Search

Home > New FDA Approvals > 024a - LATE EDITION: GSK’s BCMA antibody-drug conjugate receives Breakthrough Therapy Designation for r/r multiple myeloma; Seattle Genetics Submits sBLA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
Podcast: New FDA Approvals
Episode:

024a - LATE EDITION: GSK’s BCMA antibody-drug conjugate receives Breakthrough Therapy Designation for r/r multiple myeloma; Seattle Genetics Submits sBLA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
Category: Science & Medicine
Duration: 00:05:03
Publish Date: 2017-11-03 11:41:39
Description:

November 3, 2017 late edition

0:37 GSK’s investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma

https://www.gsk.com/en-gb/media/press-releases/gsk-s-investigational-bcma-antibody-drug-conjugate-receives-breakthrough-therapy-designation-from-us-fda-for-relapsed-and-refractory-multiple-myeloma/

2:21 Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma

http://investor.seattlegenetics.com/mobile.view?c=124860&v=203&d=1&id=2313803
Total Play: 0